Welcome to our dedicated page for Innovate SEC filings (Ticker: VATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Three businesses—steel construction, cutting-edge medical devices, and over-the-air broadcasting—sit inside Innovate Corp’s (NYSE: VATE) 300-page annual report. Finding where DBM Global’s project backlog ends and Pansend’s clinical-trial costs begin can be a full-time job. That’s why this page surfaces every Innovate Corp SEC filing explained simply, from spectrum-license 8-K updates to life-sciences R&D spend hidden in footnotes.
Our AI reads each new document the moment it hits EDGAR, then delivers plain-English answers to the questions professionals ask most: “Where is the Innovate Corp quarterly earnings report 10-Q filing?�, “Show me Innovate Corp insider trading Form 4 transactions�, or “How does the latest 8-K affect segment revenue guidance?� You’ll see instant summaries, red-flag highlights, and side-by-side metrics—so you can compare steel-fabrication margins, drug-development milestones, and broadcast cash flow without scrolling through exhibits.
Whether you monitor Innovate Corp executive stock transactions Form 4, need the Innovate Corp proxy statement executive compensation tables, or want the Innovate Corp annual report 10-K simplified, everything is here in real time. Click into any filing type�10-K, 10-Q, 8-K, S-4, or Form 4—and our platform shows how each disclosure connects back to infrastructure backlog, FDA submissions, or FCC licence values. No more hunting for footnotes: Stock Titan’s expert analysis translates technical language, tracks material events, and alerts you to Innovate Corp Form 4 insider transactions real-time. Understand Innovate faster, act sooner, and make informed decisions with AI-powered clarity.
INNOVATE Corp. (NYSE: VATE) filed an 8-K to disclose preliminary results of its previously announced exchange offer and consent solicitation for its 8.5% Senior Secured Notes due 2026. According to the 31 July 2025 filing (Item 8.01), eligible holders that tendered their notes by 5:00 p.m. ET on 30 July 2025 will receive newly issued 10.5% Senior Secured Notes due 2027 plus the Total Early Exchange Consideration. The company also extended the ability to receive this early-bird consideration through the final Expiration Deadline, aiming to maximise participation. Numeric take-up levels and revised terms were not included in the filing but are expected in Exhibit 99.1 (press release). No other financial statements were furnished. The transaction lowers near-term refinancing pressure by pushing maturity out one year, but comes at a higher coupon, signalling a higher cost of capital.
On 30 Jul 2025, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) filed a Form S-8 to register securities issuable under its Amended and Restated 2011 Equity Incentive Plan. The company is a Delaware large accelerated filer headquartered in Carlsbad, CA.
The filing automatically becomes effective and incorporates by reference Ionis� 2024 Form 10-K, Q1–Q2 2025 Form 10-Qs, and multiple 2025 Form 8-Ks, ensuring investors have access to the latest financial and governance disclosures. Exhibits include charter documents, the full equity plan, option and RSU templates, the auditor’s consent, and the legal opinion of Chief Legal Officer Patrick R. O’Neil, who owns <1 % of outstanding shares.
Standard DGCL §145 indemnification protections for directors and officers are reiterated. No underwriters are involved, no new financial results are provided, and the number of shares or aggregate offering price is not disclosed in the excerpt. Overall, the submission is routine, aimed at refreshing Ionis� ability to grant equity-based compensation without materially changing its capital structure.
INNOVATE Corp. (NYSE: VATE) filed a Form 8-K to disclose an Item 8.01 � Other Events. On 28 July 2025 the company released a press statement entitled “INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend,� which is furnished as Exhibit 99.1. The filing clarifies that the exhibit is provided for information only and is not deemed filed under Section 18 of the Exchange Act or incorporated into any Securities Act filing unless specifically referenced. No financial statements, pro-forma data, or guidance accompany this report, and no dollar amount, record date or payment date for the dividend is included in the 8-K text.
Key take-away for investors: the disclosure signals that DBM Global, a wholly-owned portfolio company, has sufficient liquidity to return cash to its equity holder(s). This may improve INNOVATE’s near-term cash inflow and could support capital allocation flexibility, but materiality cannot be assessed without the dividend size.
FAQ
What is the current stock price of Innovate (VATE)?
What is the market cap of Innovate (VATE)?
What industries does Innovate Corp operate in?
How does Innovate Corp generate revenue?
What is the role of DBM Global Inc. in Innovate Corp's portfolio?
What innovations is Pansend Life Sciences known for?
What does HC2 Broadcasting Holdings Inc. do?
How does Innovate Corp differentiate itself from competitors?
What challenges does Innovate Corp face?
How does Innovate Corp integrate its subsidiaries?
What is Innovate Corp's commitment to stakeholder capitalism?
What sectors are critical to Innovate Corp's long-term strategy?
